Yesterday, the FDA Oncologic Drugs Advisory Committee voted 12-1 against recommending the use of erlotinib as first-line maintenance monotherapy for patients with advanced non-small cell lung cancer…

The most common adverse events with erlotinib were rash and diarrhea, according to data presented. Ronald Richardson, MD, of the division of medical oncology at the Mayo Clinic in Rochester, Minn., was one of the panelists who voted against the therapy. “We were presented with a single study that has some design flaws showing so

HemOnc Today, 12/17/09

Tags: Cancer, erlotinib, Lung Cancer